Is NICE looking for more influence in new drug pricing plan?
An unprecedented attack last week on pharmaceutical prices by NICE chairman Michael Rawlins, signals a controversial new role for the UK health watchdog in the forthcoming overhaul of drugs pricing, experts say
UK cancer specialists “not telling patients about new drugs”
A quarter of doctors specialising in the cancer myeloma have admitted not telling their patients about expensive new drugs which have yet to be appraised by NICE.
ProStrakan geared up for transforming Sancuso launch in USA
Scotland-based speciality pharmaceuticals group ProStrakan has posted its financials for the first half of 2008 which show that revenues rose 26% while losses continue to narrow
|
 |
Calls for govt to introduce blanket hepatitis B vaccination
The UK government is being urged to vaccinate all children against hepatitis B and finally comply with World Health Organisation guidelines
NICE hits back after attack by oncologists
NICE has rejected a group of leading oncologists' strong criticisms of its drug assessment methods and has again attacked drugmakers’ pricing practices.
Conservatives: polyclinics will draw 25% of patients away from GP practice
New figures from the Conservative Party suggest that polyclinics will gain an average of 400 patients from each nearby GP practice – 25% of the average practice’s list size.
|